otlertuzumab
mAbexperimental
Otlertuzumab (TRU‐016) is a humanized monoclonal antibody that targets CD37 designed for the treatment of cancer. — Wikipedia
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2008 (NCT00614042)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Leukocyte antigen CD37BINDING AGENT
CD37 binding agent
- Leukocyte antigen CD37Supplementation
CD37 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaOtlertuzumab ↗
- ChEMBLCHEMBL3039539 ↗
Also known as
- otlertuzumab
- otlertuzumab
- otlertuzumab
- tru 016
- tru-016
- tru-016
- tru-016
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01644253 | Phase 1 | Sep 1, 2012 | Aptevo Therapeutics |
| NCT01317901 | Phase 1 | May 1, 2011 | Aptevo Therapeutics |
| NCT01188681 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2010 | Aptevo Therapeutics, Emergent BioSolutions |
| NCT00614042 | Phase 1 | Jan 1, 2008 | Aptevo Therapeutics |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aptevo Therapeutics | For profit | 4 | 4 | 2 | 2008 |
| Emergent BioSolutions | For profit | 1 | 0 | 1 | 2010 |
2 organizations
Page 1 / 1